S
531569
vs
B
BSE Sensex 30
Over the past 12 months, SANJIVIN has underperformed BSE Sensex 30, delivering a return of -39% compared to the BSE Sensex 30's +1% growth.
Stocks Performance
531569 vs BSE Sensex 30
Performance Gap
531569 vs BSE Sensex 30
Performance By Year
531569 vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sanjivani Paranteral Ltd
Glance View
Sanjivani Paranteral Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, anti-spasmodic, multivitamin, nutrition, iron, NSAID and analgesic, analgesic anti spasmodic, analgesic, and NSAID. Its antibiotic includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic includes Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamin include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride. Its Iron includes iron Sucrose. Its analgesic includes Metamizole.
